Tender Offers: How They Work and the Rules That Govern Them

A tender offer differs from a merger because the bidder buys shares directly from individual shareholders rather than negotiating a single transaction approved by the target's board and a shareholder vote, which makes the tender offer a tool that can be used even without board support.

The two are different routes to an acquisition. In a traditional merger, the target's board negotiates and approves the deal, and shareholders typically vote to approve it; the transaction binds all shareholders once approved. In a tender offer, the bidder makes its offer directly to shareholders, who individually decide whether to tender, so control can shift based on how many shares are tendered rather than a single vote. Tender offers and mergers are often combined: a bidder may complete a tender offer and then use a back-end merger to acquire any remaining shares. The direct nature of a tender offer is what makes it usable in a hostile bid, when the board will not negotiate.

The direct-purchase mechanism sets tender offers apart. Corporate acquisition by tender offer can proceed without the board approval that a negotiated merger requires.

Tender offers take several forms, including any-and-all versus partial offers, cash versus exchange (stock) offers, friendly versus hostile bids, and issuer self-tenders where a company buys back its own shares, each with different mechanics and legal considerations.

The variations matter for both structure and regulation. An any-and-all offer seeks every share, while a partial offer seeks a set percentage, triggering pro rata acceptance rules if oversubscribed. A cash offer pays cash, while an exchange offer pays in the bidder's securities; if the bidder offers its own securities instead of cash, the transaction may require Securities Act registration or an available exemption, in addition to the tender-offer rules. A friendly offer has board support; a hostile offer proceeds over board opposition and often meets defenses. Third-party tender offers generally involve Schedule TO and Regulation 14D, while issuer tender offers, or self-tenders, are governed by Rule 13e-4 and can form part of a going-private transaction subject to Rule 13e-3's heightened requirements.

The form determines the applicable rules. Business acquisition transactions structured as tender offers vary significantly depending on whether they are partial, exchange, hostile, or issuer offers.

A bidder making a tender offer must file detailed disclosure with the SEC, typically a Schedule TO, while a person crossing 5% beneficial ownership must file a Schedule 13D, generally within five business days, and the target must respond on Schedule 14D-9.

Disclosure runs throughout the process, and the deadlines have tightened. A person or group that crosses 5% beneficial ownership generally must assess Schedule 13D reporting, with the initial Schedule 13D now generally due within five business days and material amendments generally due within two business days, keeping the market informed of accumulations that can signal a takeover. When the bidder launches a tender offer, it files a Schedule TO setting out the terms, identity, source of funds, and plans for the target. The target's board must then file a Schedule 14D-9 stating its position, recommending that shareholders accept, reject, or take no position, with reasons. These filings ensure shareholders and the market can evaluate the offer and the response.

Accurate, complete disclosure is mandatory. Disclosure statements in a tender offer must give shareholders the information the securities rules require to make an informed decision.

SEC rules traditionally require a tender offer to remain open for at least 20 business days, give shareholders the right to withdraw tendered shares while the offer is open, require pro rata acceptance in oversubscribed partial offers, and mandate equal treatment through the all-holders and best-price rules.

These procedural protections give shareholders a fair, informed choice. The traditional rule requires a tender offer to remain open for at least 20 business days, though a 2026 SEC exemptive order permits a 10-business-day minimum for certain qualifying fixed-price, all-cash equity tender offers that meet the order's conditions, so the available timeline should be confirmed for each deal. Changes to the offer can extend or restart the period. Shareholders who tender can withdraw their shares while the offer remains open, so they are not locked in if a better option emerges. In an oversubscribed partial offer, the bidder must take shares pro rata. The all-holders rule requires the offer be open to all holders of the class, and the best-price rule requires that all tendering shareholders receive the highest consideration paid to any holder.

These rules protect shareholders from a pressured decision. Securities litigation over a tender offer often involves alleged violations of the timing, withdrawal, or equal-treatment requirements.

A target board facing a hostile tender offer can use defenses such as a poison pill (shareholder rights plan), staggered board, or seeking alternative bidders, but these defenses are constrained by the directors' fiduciary duties and are reviewed by courts under heightened standards.

Takeover defenses are tools, not a blank check. The most prominent is the poison pill, a shareholder rights plan that makes acquiring control prohibitively expensive without board cooperation, effectively forcing a bidder to negotiate. Other measures include staggered boards that slow a change of control, seeking a friendly alternative bidder (a "white knight"), and various structural defenses. But because these defenses can entrench management and affect shareholders' ability to accept a premium, courts review them under heightened scrutiny: the board generally must show a reasonable basis for believing the offer threatened the company and that its response was proportionate. When a sale of control becomes inevitable, directors' duties may shift toward maximizing shareholder value.

Defenses are powerful but legally constrained. A target board facing an unsolicited offer may need takeover defense analysis before adopting or modifying a poison pill.

In responding to a tender offer, a target board owes fiduciary duties of care and loyalty to the company and its shareholders, meaning it must make an informed decision, act in good faith and in the shareholders' interests, and avoid entrenchment, with its conduct subject to judicial review.

The board's duties shape every response. Directors must inform themselves about the offer and the company's value, often with financial and legal advisers, and act in good faith rather than to protect their own positions. When they adopt defenses, courts examine whether the board reasonably perceived a threat and responded proportionately, rather than simply entrenching itself, and when a breakup or change of control becomes inevitable, the duty may focus on obtaining the best value reasonably available. This analysis often draws heavily on Delaware takeover law, but the company's state of incorporation, its charter documents, and the specific board process all matter. A board that follows a careful, well-advised process is far better positioned to defend its decisions.

The board's process is what courts examine. Breach of fiduciary duty claims can follow a tender-offer response that shareholders believe failed these standards.

Bidders and boards face risks including disclosure violations, anti-fraud claims, and litigation over the offer's terms for bidders, and fiduciary-duty claims and challenges to defensive measures for boards, all of which can lead to injunctions, damages, or a derailed transaction.

The exposure runs both ways. A bidder that files inadequate or misleading disclosure, violates the timing or equal-treatment rules, or runs afoul of the anti-fraud provisions can face SEC scrutiny, litigation, and injunctions that delay or block the offer. A target board that mishandles its response, adopts disproportionate defenses, or fails its fiduciary duties can face shareholder litigation and court orders unwinding its measures. Both sides also face the practical risk that litigation, regulatory delay, or a competing bid derails the transaction. Recognizing these risks early, and building a compliant, well-documented process, is the best protection for both bidders and boards.

The risks are significant on both sides. Acquisition disputes and contested tender offers frequently generate litigation over disclosure, terms, and board conduct.

When a tender offer arrives, shareholders should consider the offered price relative to the stock's value, the board's recommendation, the conditions and timing of the offer, and, for unusual offers like mini-tenders, whether the offer carries the protections of a regulated tender offer at all.

Shareholders make the ultimate decision. They should weigh the premium against their view of the company's value, consider the board's recommendation and reasoning on Schedule 14D-9, and understand the offer's conditions, timing, and their withdrawal rights. A particular caution applies to mini-tender offers, which seek less than 5% of a company's shares and may avoid many of the disclosure, withdrawal, and procedural protections that apply to larger tender offers. These are sometimes made at prices below the current market and can mislead investors who assume the usual protections apply, so a shareholder should compare the offer price, the market price, the conditions, and any withdrawal rights before tendering.

Shareholders benefit from understanding the offer's nature. Shareholder disputes can arise when investors believe an offer was coercive, inadequate, or inadequately disclosed.

A tender offer is a public offer by a bidder to buy shares directly from a company's shareholders, usually at a premium to the market price and within a set period, often as a way to acquire control. Instead of negotiating only with the target's board, the bidder invites shareholders to "tender," or sell, their shares at the offered price. The offer can be for all shares or a portion, and it can be friendly (board-supported) or hostile (made over the board's objection). Because it is a broad solicitation to public shareholders, a tender offer triggers the Williams Act and SEC rules, which require detailed disclosure, a minimum offering period, withdrawal rights, and equal treatment of shareholders.

The key difference is how the deal reaches shareholders. In a merger, the target's board negotiates and approves the transaction, and shareholders typically vote on it; once approved, it binds all shareholders. In a tender offer, the bidder goes directly to shareholders, who individually decide whether to tender their shares, so control shifts based on how many shares are tendered rather than a single vote. Because it is direct, a tender offer can be used even in a hostile situation where the board will not negotiate. Tender offers and mergers are often combined, with a bidder completing a tender offer and then using a back-end merger to acquire any remaining shares.

Generally, a tender offer must remain open for at least 20 business days under SEC rules, which gives shareholders time to consider it. However, a 2026 SEC exemptive order permits a 10-business-day minimum for certain qualifying fixed-price, all-cash equity tender offers that meet the order's specific conditions, which can accelerate some friendly all-cash deals. Most offers still require careful timing analysis, because changes to the offer can extend or restart the clock, and the shorter period is available only when the conditions are satisfied. The available timeline should be confirmed for each transaction rather than assumed.

A person or group that crosses 5% beneficial ownership of a public company's voting stock generally must evaluate Schedule 13D reporting, which discloses the stake and intentions. Under SEC amendments that shortened these deadlines, the initial Schedule 13D is now generally due within five business days, and material amendments are generally due within two business days. These filings keep the market informed of significant accumulations, which can signal a potential takeover. Certain passive investors may instead report on a different schedule with different timing. Because the deadlines are short and the rules detailed, the reporting obligation should be assessed as soon as the threshold is approached.

Yes, but its defenses are constrained by the board's fiduciary duties. A target board facing a hostile tender offer can use measures such as a poison pill (a shareholder rights plan that makes acquiring control without board cooperation prohibitively costly), a staggered board, or seeking a friendly alternative bidder. However, because these defenses can entrench management and affect shareholders' ability to accept a premium, courts review them under heightened scrutiny, generally requiring the board to show it reasonably perceived a threat and responded proportionately. This analysis often draws on Delaware takeover law, but the company's state of incorporation and board process matter. When a change of control becomes inevitable, the duty may shift toward obtaining the best value reasonably available.

A mini-tender offer is an offer to buy less than 5% of a company's shares. Because it falls below that threshold, it avoids many of the disclosure, withdrawal, and procedural protections that the Williams Act and SEC rules require for larger tender offers. Regulators have cautioned that mini-tender offers are sometimes made at prices below the current market price and can mislead investors who assume they carry the usual protections, and that withdrawal rights may be limited. If you receive a mini-tender offer, it is worth comparing the offer price to the current market price and checking the offer's terms, conditions, and any withdrawal rights carefully, because the protections you might expect from a standard tender offer may not apply.